Ventana gets rabbit antibody co for $29m
This article was originally published in Clinica
Executive Summary
Taking time out from fending off Roche's hostile takeover, Ventana Medical Systems has acquired developer of rabbit monoclonal antibodies Spring BioScience in a $28.9m all-cash deal. The transaction included an extra $11.7m in milestone payments over the next two years.